50 mg semaglutide Efficacy and safety of once-daily oral 25 and mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial related medical problems Novo Nordisk wins EU approval

Understanding the benefits and risks of GLP-1 medications is key for making informed choices

Managing multiple medications is crucial while taking semaglutide to avoid potential drug interactions, ensure effectiveness, and minimize side effects

What the Research Shows The approval was based on impressive results from the SURMOUNT-OSA clinical trials involving 469 adults: For people NOT using CPAP machines: Tirzepatide reduced breathing interruptions by 25 events per hour Placebo only reduced interruptions by 5 events per hour 42% achieved remission or mild symptoms after one year For people USING CPAP machines: Tirzepatide reduced breathing interruptions by 29 events per hour Placebo only reduced interruptions by 6 events per hour 50% achieved remission or mild symptoms after one year Beyond Sleep Apnea While sleep apnea research is most advanced, early evidence suggests GLP-1 medications may help with other sleep problems too: Reduced insomnia symptoms Less tossing and turning at night Improved deep sleep quality Better daytime energy levels Who Can Benefit From GLP-1 Therapy for Sleep

The GH secretagogue component restores growth hormone pulses that decline with age

The drug used was Rybelsus, an oral version of semaglutide normally prescribed for type 2 diabetes